Comerica Bank Sells 720,532 Shares of ADMA Biologics Inc $ADMA

Comerica Bank reduced its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 93.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 52,102 shares of the biotechnology company’s stock after selling 720,532 shares during the quarter. Comerica Bank’s holdings in ADMA Biologics were worth $950,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC boosted its position in shares of ADMA Biologics by 11.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 634 shares in the last quarter. Cim LLC boosted its position in shares of ADMA Biologics by 0.7% during the third quarter. Cim LLC now owns 91,486 shares of the biotechnology company’s stock valued at $1,341,000 after purchasing an additional 665 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 700 shares in the last quarter. Clearstead Advisors LLC boosted its position in shares of ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 795 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in shares of ADMA Biologics by 1.7% during the third quarter. Oppenheimer & Co. Inc. now owns 49,230 shares of the biotechnology company’s stock valued at $722,000 after purchasing an additional 835 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 3.5%

ADMA Biologics stock opened at $8.17 on Friday. The company has a current ratio of 6.95, a quick ratio of 3.74 and a debt-to-equity ratio of 0.51. The business’s fifty day simple moving average is $12.12 and its two-hundred day simple moving average is $15.47. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $22.37. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 12.01 and a beta of 0.83.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same period in the previous year, the company posted $0.11 earnings per share. The company’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities analysts predict that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Negative Sentiment: ADMA reported Q1 EPS of $0.19, in line with estimates, but revenue came in below expectations at $114.5 million versus consensus near $140 million, raising concerns about growth momentum. ADMA Biologics, Inc. Q1 2026 Earnings Call Summary
• Negative Sentiment: Management lowered its 2026 revenue outlook to $530 million-$560 million and withdrew long-term guidance, signaling more caution around near-term demand and competitive pressure in the immunoglobulin market. ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and possible misleading disclosures, adding headline risk and increasing uncertainty for shareholders. ROSEN, LEADING INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation – ADMA
• Negative Sentiment: Additional firms, including Lowey Dannenberg, Pomerantz, Kehoe, Block & Leviton, and BFA Law, also launched or promoted investigations, reinforcing the market’s concern that the earnings update could lead to litigation. Lowey Dannenberg, P.C. is Investigating ADMA Biologics (NASDAQ: ADMA)

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms bought 7,000 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was bought at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the acquisition, the director directly owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 3.90% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on ADMA. Zacks Research lowered ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Canaccord Genuity Group dropped their price target on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Mizuho dropped their price target on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.00.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.